Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial

被引：0
|
作者：
Dena R. Howard
Talha Munir
Anna Hockaday
Andy C. Rawstron
Laura Collett
Jamie B. Oughton
David Allsup
Adrian Bloor
David Phillips
Peter Hillmen
机构：
[1] University of Leeds,Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research
[2] St James’s University Hospital,St James’s Institute of Oncology
[3] St James’s University Hospital,Haematological Malignancy Diagnostic Service, St James’s Institute of Oncology
[4] Hull and East Yorkshire Hospitals NHS Trust,Department of Haematology, Queens Centre for Oncology and Haematology, Castle Hill Hospital
[5] University of Manchester,Department of Haematology, The Christie NHS Foundation Trust
[6] Manchester Academic Health Sciences Centre,undefined
来源：
Trials | / 17卷
关键词：
CLL, Chronic lymphocytic leukaemia; Ofatumumab; FC; Bendamustine; Phase II trial; MRD, Minimal residual disease; Dose selection; Relapsed population; Randomised clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [1] Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial
    Howard, Dena R.
    Munir, Talha
    Hockaday, Anna
    Rawstron, Andy C.
    Collett, Laura
    Oughton, Jamie B.
    Allsup, David
    Bloor, Adrian
    Phillips, David
    Hillmen, Peter
    TRIALS, 2016, 17
  • [2] COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study
    Allsup, David
    Howard, Dena
    Emmerson, Jake
    Hockaday, Anna
    Rawstron, Andy
    Oughton, Jamie B.
    Bloor, Adrian
    Phillips, David
    Nathwani, Amit
    Paneesha, Shankara
    Turner, Deborah
    Munir, Talha
    Hillmen, Peter
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (03) : 646 - 650
  • [3] COSMIC, a phase II randomised study investigating the efficacy of standard or high-dose ofatumumab in combination with chemotherapy in patients with relapsed chronic lymphocytic leukaemia
    Allsup, David
    Howard, Dena
    Munir, Talha
    Hockaday, Anna
    Rawstron, Andy
    Collett, Laura
    McParland, Lucy
    Oughton, Jamie
    Bloor, Adrian
    Phillips, David
    Nathwani, Amit
    Shankara, Paneesha
    Turner, Deborah
    Hillmen, Peter
    LEUKEMIA & LYMPHOMA, 2017, 58 : 112 - 113
  • [4] A PHASE II RANDOMISED STUDY INVESTIGATING THE EFFICACY OF STANDARD OR HIGH-DOSE OFATUMUMAB IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA
    Allsup, D.
    Howard, D.
    Munir, T.
    Hockaday, A.
    Rawstron, A.
    Collett, L.
    McParland, L.
    Oughton, J.
    Bloor, A.
    Phillips, D.
    Nathwani, A.
    Shankara, P.
    Turner, D.
    Hillmen, P.
    HAEMATOLOGICA, 2017, 102 : 72 - 72
  • [5] Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial
    Laura Collett
    Dena R. Howard
    Talha Munir
    Lucy McParland
    Jamie B. Oughton
    Andy C. Rawstron
    Anna Hockaday
    Claire Dimbleby
    David Phillips
    Kathryn McMahon
    Claire Hulme
    David Allsup
    Adrian Bloor
    Peter Hillmen
    Trials, 18
  • [6] Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial
    Collett, Laura
    Howard, Dena R.
    Munir, Talha
    McParland, Lucy
    Oughton, Jamie B.
    Rawstron, Andy C.
    Hockaday, Anna
    Dimbleby, Claire
    Phillips, David
    McMahon, Kathryn
    Hulme, Claire
    Allsup, David
    Bloor, Adrian
    Hillmen, Peter
    TRIALS, 2017, 18
  • [7] Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)
    Falchi, Lorenzo
    Keating, Michael J.
    Badoux, Xavier C.
    Wierda, William G.
    O'Brien, Susan Mary
    Smith, Susan C.
    Wen, Sijin
    Kantarjian, Hagop
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
    Ferrajoli, Alessandra
    Falchi, Lorenzo
    O'Brien, Susan
    Wierda, William
    Faderl, Stefan
    Smith, Susan C.
    Ayala, Ana B.
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2012, 120 (21)
  • [9] Phase II trial of epirubicin at standard dose in relapsed ovarian cancer
    Pelaez, I
    Lacave, AJ
    Palacio, I
    Alvarez, E
    Cueva, JF
    Muniz, I
    Arranz, F
    Fra, J
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (05) : 899 - 900
  • [10] Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL
    Hillmen, Peter
    Milligan, Donald
    Schuh, Anna
    McParland, Lucy
    Chalmers, Anna
    Munir, Tahla
    Varghese, Abraham M.
    Rawstron, Andy C.
    Allsup, David J.
    Marshall, Scott
    Smith, Alex
    Collett, Corinne
    Gregory, Walter
    Duncombe, Andrew
    Cohen, Dena
    BLOOD, 2013, 122 (21)
12345